Evaluation of the Perfusion of the Pancreatic Remnant With Indocyanine Green and Its Impact on the Reduction of Pancreatic Fistula After Pancreaticoduodenectomy
Recruiting
N/A
Interventional Study
Postoperative Pancreatic Fistula Post-pancreatoduodenectomy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 40 (estimated)
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Postoperative pancreatic fistula (POPF) is the most common complication following cephalic duodenopancreatectomy (DPC) and is a key determinant of severe postoperative morbidity and mortality. Despite numerous trials aimed at reducing POPF incidence, it remains high, ranging between 3% and 45%. The exact pathophysiology of pancreatic fistulas is not fully understood, but studies suggest that they …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients for whom a Cephalic Pancreaticoduodenectomy is indicated.
* Age over 18 years.
* Informed consent (IC) signed by the patient and the investigator
Exclusion Criteria:
* Patients in whom it was not possible to perform a pancreaticojejunal anastomosis using the Blumgar…
Contacts
No contact information available.